Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

NCT02727881 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration

Interventions

DRUG: Squalamine lactate ophthalmic solution, 0.2%
DRUG: Placebo Ophthalmic solution
DRUG: ranibizumab

Sponsor

Ohr Pharmaceutical Inc.